Bio-Techne (TECH) Non-Current Assets (2009 - 2026)
Bio-Techne's (TECH) quarterly Non-Current Assets came in at $1.9 billion in Q1 2026, down 7.66% year-on-year from $2.0 billion in Q1 2025, and down 1.2% quarter-over-quarter from $1.9 billion in Q4 2025.
Bio-Techne (TECH) Non-Current Assets (2009 - 2026) Analysis & Trends
Bio-Techne's Non-Current Assets history runs 18 years deep, the most recent figure standing at $1.9 billion for Q1 2026.
- On a quarterly basis, Non-Current Assets fell 7.66% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $7.6 billion, a 7.45% decrease from a year earlier, with the FY2025 full-year figure at $1.9 billion, down 6.56% from the prior year.
- Non-Current Assets slipped to $1.9 billion in Q1 2026 per TECH's latest filing, from $1.9 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $2.2 billion in Q3 2023 and bottomed at $1.7 billion in Q2 2022.
- The 5-year median for Non-Current Assets is $2.0 billion (2025), against an average of $2.0 billion.
- Across the five-year window, Non-Current Assets increased 20.3% in 2023 and dropped 8.18% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $1.8 billion in 2022, then rose by 19.01% to $2.1 billion in 2023, then slipped by 4.87% to $2.0 billion in 2024, then dropped by 7.39% to $1.9 billion in 2025, then slipped by 1.2% to $1.9 billion in 2026.
- Per Business Quant, the three latest TECH Non-Current Assets figures stand at $1.9 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Bio-Techne | 11.23 Bn | 11.02 Bn | 208.29 Mn | 1.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.86 Bn |
| Dec 31, 2025 | 1.89 Bn |
| Sep 30, 2025 | 1.92 Bn |
| Jun 30, 2025 | 1.95 Bn |
| Mar 31, 2025 | 2.02 Bn |
| Dec 31, 2024 | 2.04 Bn |
| Sep 30, 2024 | 2.09 Bn |
| Jun 30, 2024 | 2.09 Bn |
| Mar 31, 2024 | 2.11 Bn |
| Dec 31, 2023 | 2.14 Bn |
| Sep 30, 2023 | 2.16 Bn |
| Jun 30, 2023 | 2.02 Bn |
| Mar 31, 2023 | 2.03 Bn |
| Dec 31, 2022 | 1.80 Bn |
| Sep 30, 2022 | 1.80 Bn |
| Jun 30, 2022 | 1.69 Bn |
| Mar 31, 2022 | 1.71 Bn |
| Dec 31, 2021 | 1.71 Bn |
| Sep 30, 2021 | 1.73 Bn |
| Jun 30, 2021 | 1.75 Bn |